Brii Biosciences Limited is a biotechnology company engaged in the research and development of therapies for infectious diseases and central nervous system disorders. The company operates in China and the United States, focusing on conditions with high unmet medical needs, including HIV, chronic hepatitis B, and postpartum depression. Its pipeline includes monoclonal antibody combinations such as Amubarvimab and Romlusevimab for COVID-19, and long-acting therapeutic candidates for HIV. Brii Biosciences utilizes its proprietary BRiSC siRNA discovery platform to advance novel treatment options. The company has established partnerships with VBI Vaccines, Vir Biotechnology, and WuXi Biologics for the development of bispecific antibody immunotherapeutics and hepatitis B functional cure strategies. Established in 2018, the group includes subsidiaries such as Brii Biosciences (Shanghai) Co. Limited, Brii Biosciences (Beijing) Co. Limited, and TSB Therapeutics (Beijing) Co. Limited.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage briibio.com
Sector Healthcare IR page briibio.com
Tags
infectious diseases, central nervous system, hiv, hepatitis b, monoclonal antibodies, sirna, postpartum depression, vaccines, clinical stage, BRiSC, Amubarvimab, Romlusevimab, BRII-179, BRII-196, BRII-198, BRII-296, BRII-732, BRII-835, VBI-2601, VIR-2218, VIR-3434, Brii Biosciences (Shanghai) Co. Limited, Brii Biosciences (Beijing) Co. Limited, Brii Biosciences (Hong Kong) Co. Limited, Brii Biosciences Offshore Limited, Brii Biosciences Pty Ltd, TSB Therapeutics (Beijing) Co. Limited
Press page briibio.com/en/media/press-release

Metrics

Valuation  
Market cap HK$ 696.91M
Market cap (USD) $ 88.815M
P/E -3.38
PEG —
P/BV 0.28
P/S 31.83
P/OCF -2.09
P/FCF —
Dividend yield —
Turnover / mcap 0.06%
Returns  
ROE -9.0%
ROI -9.6%
ROIC -9.6%
Profit margin -1,196.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 18.605M 0 617K 51.626M 0 —
Net profit -222.624M -508.162M -174.829M -484.312M -4.164B -1.19B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 1.68 0.92 2.34 8.82 27.86 —
Price performance 12m 0.86 -0.6 -0.75 -0.7 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Oct 29, 2026

Back

Brii Bio to Present Late-Breaking Data from Its Phase 2b ENRICH and ENHANCE Studies in Participants with Chronic Hepatitis B Virus Infection at AASLD 2026

DURHAM, N.C., United States / BEIJING, China – Oct 29**, 202****6** – Brii Biosciences Limited  (“Brii Bio” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced that end-of-treatment (“EOT”) and follow-up results from its Phase 2b ENRICH and ENHANCE studies will be presented in three late-breaking presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Denver, Colorado, from November 5 to 9, 2026.

The ENRICH and ENHANCE studies are two Phase 2b studies designed to further define the role of BRII-179 in the treatment of chronic hepatitis B virus (“HBV”) infection and inform the selection of an optimal combination regimen for future development.

  • The ENRICH study evaluates BRII-179 as a priming therapy administered prior to elebsiran and pegylated interferon alpha (“PEG-IFNα”) treatment.
  • The ENHANCE study evaluates whether the triple combination of BRII-179, elebsiran, and PEG-IFNα further enhances hepatitis B surface antigen (“HBsAg”) loss.

        − Part A1 of the ENHANCE study evaluates a concurrent triple combination regimen of BRII-179, elebsiran, and PEG-IFNα.

        − Part A2 of the ENHANCE study evaluates a sequential combination approach designed to potentially shorten PEG-IFNα therapy by administering BRII-179 plus elebsiran during the first 24 weeks followed by 24 weeks of elebsiran and PEG-IFNα.

EOT and 24-week follow-up results from the ENRICH study and Part A1 of the ENHANCE study will each be presented in a late-breaking oral presentation. EOT and 8-week follow-up results from Part A2 of the ENHANCE study will be presented in a late-breaking poster presentation.

Oral presentation details are as follows:

Title**:** Efficacy and safety of sequential BRII-179, elebsiran, and pegylated interferon alfa therapy in chronic hepatitis B virus infection: end-of-treatment and follow-up results from the phase 2 ENRICH study

Session**:** Late Breaking Abstract Parallel Session 2

Date: November 8, 2026

Time: 5:45 pm - 6:00 pm, MST (UTC-7)

Publication Number: 5009

Presenter:  Jinlin Hou, M.D., Director of Institue of Hepatology of Guangdong, Director of Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Department of Infectious Diseases & Hepatology Unit, Nanfang Hospital, Southern Medical University

Title: Elebsiran plus BRII-179 and peginterferon alfa achieve greater HBsAg loss and enhanced immune responses compared with peginterferon alfa alone in virologically suppressed chronic hepatitis B: Results from the Phase 2 ENHANCE Part A-1

Session: Late Breaking Abstract Parallel Session 3

Date: November 9, 2026

Time: 11:30 am - 11:45 am, MST (UTC-7)

Publication Number: 5017

Presenter: David Margolis, M.D., M.P.H., Chief Medical Officer of Brii Biosciences

Poster presentation details are as follows:

Title: Immune Priming With BRII-179 and Elebsiran Enables Shortened Pegylated Interferon Alfa Treatment While Maintaining HBsAg Loss in Participants With Chronic HBV Infection: Results From ENHANCE Part A2

Session: Late Breaking Posters ("5019-5041")

Date: November 8, 2026

Time: 1:00 pm - 2:00 pm, MST (UTC-7)

Publication Number: 5029

Prompts

Brii Biosciences Limited (ticker 2137), listed in Hong Kong.

ETFs Holding Brii Biosciences Limited

ETF Weight in ETF Shares Market value As of
AVEM 0.00% 288,500 $ 37.26K Nov 16, 2026
AVSE 0.00% 28,500 $ 3,680.81 Nov 16, 2026